Fluoroquinolone resistance: mechanisms and epidemiology.
Tillotson
G S
GS
Bayer Corporation, West Haven, CT 06516, USA.
Dorrian
I
I
Blondeau
J
J
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D001424:Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D004250:DNA Topoisomerases, Type II / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D003906:Developing Countries / Q000706:statistics & numerical data; D004352:Drug Resistance, Microbial / Q000502:physiology; D005060:Europe / Q000453:epidemiology; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009154:Mutation; D014481:United States / Q000453:epidemiology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D004250:DNA Topoisomerases, Type II